News

January 16, 2020January 16, 2020

Qletli, Biosimilar to Humira, Now Available in China to Treat Certain Autoimmune Diseases

News

Qletli, a biosimilar to Humira (adalimumab), is now available in China for the treatment of three autoimmune diseases, including ankylosing spondylitis (AS). The medication is also approved for the ... Read more

January 13, 2020January 13, 2020

Levels of DNASE1L3 Protein Are Potential Biomarker of Ankylosing Spondylitis, Study Suggests

News

Analyzing the levels of a protein called DNASE1L3 may enable an accurate diagnosis of ankylosing spondylitis (AS), a study suggests. Besides being able to distinguish between AS and generalized ... Read more

January 9, 2020January 9, 2020

Mabpharm Seeks Approval of Infliximab Biobetter in China

News

Mabpharm has filed an application with China’s National Medical Products Administration (NMPA) seeking approval of a biobetter of infliximab, a biological treatment for people with ankylosing spondylitis and other inflammatory ... Read more

January 6, 2020January 6, 2020

nr-axSpA Patients Less Likely to be Treated With Biologics Than Those With Ankylosing Spondylitis, US Survey Shows

News

Despite experiencing similar symptoms, people with non-radiographic axial spondyloarthritis (nr-axSpA) are less likely to be treated with a biologic therapy than those with ankylosing spondylitis (AS), according to a ... Read more

January 2, 2020January 2, 2020

First Patient Dosed in Phase 3 Trial in China Testing Enbrel Biosimilar SCB-808

News

The first ankylosing spondylitis (AS) patient has been dosed in a Phase 3 trial testing SCB-808, a potential biosimilar of Enbrel (etanercept) being developed for the treatment of rheumatic diseases in ... Read more

December 19, 2019December 19, 2019

Inflammation May Lead to Underestimating Efficacy of TNF Inhibitors, Study Suggests

News

The efficacy of TNF inhibitors in slowing disease progression in people with ankylosing spondylitis (AS) may be underestimated due to inflammation when treatment is started, new research suggests. The ... Read more

December 16, 2019December 16, 2019

AS Patients on Taltz Treatment Experienced Less Fatigue and Pain, and Better Sleep Over 1 Year, Phase 3 Trials Show

News

Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to one year, results from two Phase 3 trials show. The data were ... Read more

December 12, 2019December 12, 2019

Simponi Aria Leads to Sustained Improvements in Quality of Life for Adults with Active AS, Phase 3 Trial Shows

News

Treatment with Simponi Aria (golimumab) led to clinically meaningful improvements in health-related quality of life in adults with ankylosing spondylitis after four months — benefits that were maintained over ... Read more

December 9, 2019December 9, 2019

FDA Approves Avsola, Remicade Biosimilar, to Treat Active Ankylosing Spondylitis

News

The U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq), a biosimilar to Remicade (infliximab), to treat active ankylosing spondylitis, its maker, Amgen, announced. The new therapy has been ... Read more

December 5, 2019

HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases

News

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s ... Read more

Pin It on Pinterest